Format
Sort by
Items per page

Send to

Choose Destination

Best matches for anti-retroviral agents AND cost effectiveness AND cost effectiveness analysis:

Search results

Items: 1 to 20 of 797

1.

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.

Tierrablanca LE, Ochalek J, Ford D, Babiker A, Gibb D, Butler K, Turkova A, Griffin S, Revill P; BREATHER (PENTA 16) Trial Group.

Medicine (Baltimore). 2018 Feb;97(5):e9698. doi: 10.1097/MD.0000000000009698.

2.

Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care.

Revill P, Walker S, Cambiano V, Phillips A, Sculpher MJ.

PLoS One. 2018 Jan 2;13(1):e0190283. doi: 10.1371/journal.pone.0190283. eCollection 2018.

3.

The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis.

Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, Myer L, Abrams EJ, Walensky RP, Leroy V, Freedberg KA, Ciaranello A.

PLoS Med. 2017 Nov 21;14(11):e1002446. doi: 10.1371/journal.pmed.1002446. eCollection 2017 Nov.

4.

HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.

Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, Saayman E, Moorhouse M, Venter WDF, Rees H; TAPS Demonstration Project Team.

PLoS Med. 2017 Nov 21;14(11):e1002444. doi: 10.1371/journal.pmed.1002444. eCollection 2017 Nov.

5.

Modelling the cost-effectiveness of HIV care shows a clear benefit when transmission risk is considered in the calculations - A message for Central and Eastern Europe.

Kowalska JD, Wójcik G, Rutkowski J, Ankiersztejn-Bartczak M, Siewaszewicz E.

PLoS One. 2017 Nov 13;12(11):e0186131. doi: 10.1371/journal.pone.0186131. eCollection 2017.

6.

Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.

Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S.

PLoS One. 2017 Oct 26;12(10):e0186496. doi: 10.1371/journal.pone.0186496. eCollection 2017.

7.

The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.

Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP.

J Infect Dis. 2017 Oct 17;216(7):798-807. doi: 10.1093/infdis/jix349.

PMID:
29029344
8.

Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid.

Walensky RP, Borre ED, Bekker LG, Hyle EP, Gonsalves GS, Wood R, Eholié SP, Weinstein MC, Anglaret X, Freedberg KA, Paltiel AD.

Ann Intern Med. 2017 Nov 7;167(9):618-629. doi: 10.7326/M17-1358. Epub 2017 Aug 29.

PMID:
28847013
9.

Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.

Venter WDF, Majam M, Akpomiemie G, Arulappan N, Moorhouse M, Mashabane N, Chersich MF.

BMC Public Health. 2017 Jul 4;17(Suppl 3):445. doi: 10.1186/s12889-017-4353-1.

10.

Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa.

Ngambi PG, Kalungia AC, Law MR, Kalemeera F, Truter I, Godman B, Munkombwe D.

Expert Rev Pharmacoecon Outcomes Res. 2017 Oct;17(5):459-467. doi: 10.1080/14737167.2017.1364161. Epub 2017 Aug 11. Review.

PMID:
28770641
11.

Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.

Pialoux G, Marcelin AG, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C.

Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):83-91. doi: 10.1080/14737167.2017.1359542. Epub 2017 Jul 31.

PMID:
28741965
12.

Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis.

Yi S, Tuot S, Mwai GW, Ngin C, Chhim K, Pal K, Igbinedion E, Holland P, Choub SC, Mburu G.

J Int AIDS Soc. 2017 Jun 26;20(1):21580. doi: 10.7448/IAS.20.1.21580. Review.

13.

Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men.

McKenney J, Chen A, Hoover KW, Kelly J, Dowdy D, Sharifi P, Sullivan PS, Rosenberg ES.

PLoS One. 2017 Jun 1;12(6):e0178170. doi: 10.1371/journal.pone.0178170. eCollection 2017. Erratum in: PLoS One. 2017 Jul 27;12 (7):e0182593.

14.

Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission.

Kinikar A, Gupte N, Bhat J, Bharadwaj R, Kulkarni V, Bhosale R, McIntire KN, Mave V, Suryavanshi N, Patil S, Bollinger R, Gupta A.

Sex Transm Dis. 2017 Jun;44(6):371-375. doi: 10.1097/OLQ.0000000000000622.

15.

Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial.

Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, Sanne I, Fox MP, Rosen S.

AIDS. 2017 Jul 17;31(11):1611-1619. doi: 10.1097/QAD.0000000000001528.

PMID:
28463879
16.

Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.

Oyagüez I, Buti M, Brosa M, Rueda M, Casado MA.

Ann Hepatol. 2017 May - Jun;16(3):358-365. doi: 10.5604/16652681.1235478.

17.

Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.

de Bruin M, Oberjé EJM, Viechtbauer W, Nobel HE, Hiligsmann M, van Nieuwkoop C, Veenstra J, Pijnappel FJ, Kroon FP, van Zonneveld L, Groeneveld PHP, van Broekhuizen M, Evers SMAA, Prins JM.

Lancet Infect Dis. 2017 Jun;17(6):595-604. doi: 10.1016/S1473-3099(16)30534-5. Epub 2017 Mar 3.

PMID:
28262598
18.

Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints.

Mikkelsen E, Hontelez JA, Jansen MP, Bärnighausen T, Hauck K, Johansson KA, Meyer-Rath G, Over M, de Vlas SJ, van der Wilt GJ, Tromp N, Bijlmakers L, Baltussen RM.

PLoS Med. 2017 Feb 21;14(2):e1002240. doi: 10.1371/journal.pmed.1002240. eCollection 2017 Feb.

19.

Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?
.

Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G.

Int J Clin Pharmacol Ther. 2017 May;55(5):381-393. doi: 10.5414/CP202775. Review.

PMID:
28211784
20.

Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.

Shattock AJ, Benedikt C, Bokazhanova A, Đurić P, Petrenko I, Ganina L, Kelly SL, Stuart RM, Kerr CC, Vinichenko T, Zhang S, Hamelmann C, Manova M, Masaki E, Wilson DP, Gray RT.

PLoS One. 2017 Feb 16;12(2):e0169530. doi: 10.1371/journal.pone.0169530. eCollection 2017.

Supplemental Content

Loading ...
Support Center